Business ❯ Finance ❯ Investments

Biotechnology

Clinical Trials CRISPR Therapeutics Capricor Therapeutics Acquisitions Biotech Stocks Pharmaceuticals Mergers and Acquisitions Gene Editing Stock Market Psychedelics

3 ARTICLES

2w ago

Moderna Repositions as an Oncology mRNA Platform After Melanoma Trial Win and $2.6 Billion Raise

Hospital readiness together with full Phase 3 results will determine whether the personalized vaccine can scale into a lasting treatment and commercial franchise.

3 ARTICLES

3w ago

Aethlon Agrees to All-Stock Merger to Take North Immunology Public

3 ARTICLES

4w ago

ARK Sells $28.6M of Alphabet to Buy Meta Shares and Add Biotech Stakes

9 ARTICLES

4w ago

Capricor Faces Securities Class Action as FDA Extends Review of Duchenne Therapy

4 ARTICLES

2mo ago

CNS Pharmaceuticals Soars 215% on $22.5 Million Oversubscribed Private Placement

3 ARTICLES

5mo ago

Merck and Other Drugmakers Weigh Bids for Inhibrx’s Keytruda-Linked Cancer Drug

3 ARTICLES

6mo ago

CRISPR Therapeutics’ Pipeline Pitched as Path to One-Time Heart Risk Treatments

4 ARTICLES

6mo ago

Serina Therapeutics Shares Jump After Private Placement to Raise Up to $63.3 Million

4 ARTICLES

6mo ago

Immutep Halts Phase III Lung Cancer Trial After Futility Call as Shares Crash

8 ARTICLES

7mo ago

Xenon to Present Topline X-TOLE2 Phase 3 Results in Focal Onset Seizures at 8 A.M. ET Today

3 ARTICLES

8mo ago

ARK Invest Deepens Pivot to AI With Fresh Buys in Tempus, WeRide and Kodiak, Cuts Twist and 10x

7 ARTICLES

8mo ago

Skye Bioscience Investors Face Friday Deadline in Securities Class Action Over Nimacimab Disclosures

3 ARTICLES

9mo ago

Jan. 16 Deadline Nears in Skye Bioscience Investor Class Actions

3 ARTICLES

9mo ago

Athira Pharma Secures Exclusive Lasofoxifene Rights, Raises $90 Million to Advance Phase 3 Breast Cancer Program

3 ARTICLES

9mo ago

Nektar’s Alopecia Drug Misses Phase 2b Goal as Company Cites Ineligible Patients, Plans Phase 3

5 ARTICLES

9mo ago

MoonLake Immunotherapeutics Investors Face Lead‑Plaintiff Deadline in Securities Fraud Suits

4 ARTICLES

10mo ago

Biotechnology

Moderna Repositions as an Oncology mRNA Platform After Melanoma Trial Win and $2.6 Billion Raise

Aethlon Agrees to All-Stock Merger to Take North Immunology Public

ARK Sells $28.6M of Alphabet to Buy Meta Shares and Add Biotech Stakes

Capricor Faces Securities Class Action as FDA Extends Review of Duchenne Therapy

FDA Staff Flags Major Flaws in Capricor’s Deramiocel Data

Akari’s AKTX-101 Shows Preclinical Synergy With KRAS Inhibitor as Stock Soars

FDA Accepts ImmunityBio Filing to Expand ANKTIVA Use in Bladder Cancer

CNS Pharmaceuticals Soars 215% on $22.5 Million Oversubscribed Private Placement

Merck and Other Drugmakers Weigh Bids for Inhibrx’s Keytruda-Linked Cancer Drug

CRISPR Therapeutics’ Pipeline Pitched as Path to One-Time Heart Risk Treatments

Never miss stories about

Biotechnology

Serina Therapeutics Shares Jump After Private Placement to Raise Up to $63.3 Million

Immutep Halts Phase III Lung Cancer Trial After Futility Call as Shares Crash

Xenon to Present Topline X-TOLE2 Phase 3 Results in Focal Onset Seizures at 8 A.M. ET Today

ARK Invest Deepens Pivot to AI With Fresh Buys in Tempus, WeRide and Kodiak, Cuts Twist and 10x

Skye Bioscience Investors Face Friday Deadline in Securities Class Action Over Nimacimab Disclosures

Jan. 16 Deadline Nears in Skye Bioscience Investor Class Actions

Athira Pharma Secures Exclusive Lasofoxifene Rights, Raises $90 Million to Advance Phase 3 Breast Cancer Program

Nektar’s Alopecia Drug Misses Phase 2b Goal as Company Cites Ineligible Patients, Plans Phase 3

MoonLake Immunotherapeutics Investors Face Lead‑Plaintiff Deadline in Securities Fraud Suits

Skye Bioscience Investors Pressed to Seek Lead Role After Class Action Filing

Never miss stories about

Biotechnology